Core Viewpoint - Sichuan Kelun Pharmaceutical Co., Ltd. announced that its subsidiary, Sichuan Kelun Botai Biopharmaceutical Co., Ltd., received approval from the National Medical Products Administration (NMPA) for the third indication of the antibody-drug conjugate (ADC) sac-TMT, targeting TROP2, for treating adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment [1][2] Group 1 - The approval is based on a randomized, open-label, multicenter Phase III clinical study (OptiTROP-Lung04), which will be presented at the 2025 European Society for Medical Oncology (ESMO) conference [2] - The study aims to evaluate the efficacy and safety of sac-TMT administered as a monotherapy compared to pemetrexed combined with platinum-based therapy in patients with EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC who failed EGFR-TKI treatment [2] - Sac-TMT is the first and only ADC to show significant overall survival (OS) benefits compared to platinum-based doublet chemotherapy in this patient population [1][2] Group 2 - In March 2025, sac-TMT was approved by NMPA for patients with EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC who progressed after EGFR-TKI and platinum-based chemotherapy [2] - The monotherapy with sac-TMT significantly extended the overall survival of these patients compared to standard treatment [2] - Another Phase III registration study of sac-TMT combined with osimertinib as first-line treatment for EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC has completed patient enrollment in China [2]

Core Viewpoint - Sichuan Kelun Pharmaceutical Co., Ltd. announced that its subsidiary, Sichuan Kelun Botai Biopharmaceutical Co., Ltd., received approval from the National Medical Products Administration (NMPA) for the third indication of the antibody-drug conjugate (ADC) sac-TMT, targeting TROP2, for treating adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment [1][2] Group 1 - The approval is based on a randomized, open-label, multicenter Phase III clinical study (OptiTROP-Lung04), which will present its findings at the 2025 European Society for Medical Oncology (ESMO) conference [2] - The study evaluates the efficacy and safety of sac-TMT administered as a monotherapy compared to pemetrexed combined with platinum-based therapy in patients with EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC who failed EGFR-TKI treatment [2] - Sac-TMT is the first and only ADC to show significant overall survival (OS) benefits compared to standard platinum-based doublet chemotherapy in this patient population [1][2] Group 2 - In March 2025, sac-TMT was approved by NMPA for patients with EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC who progressed after EGFR-TKI and platinum-based chemotherapy [2] - The monotherapy with sac-TMT significantly extended the overall survival of these patients compared to standard treatment [2] - Another Phase III registration study of sac-TMT combined with osimertinib as first-line treatment for EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC has completed patient enrollment in China [2]

Core Viewpoint - The approval of sac-TMT, a targeted antibody-drug conjugate (ADC) by Kelun Pharmaceutical's subsidiary, marks a significant advancement in the treatment of advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with EGFR mutations after progression on EGFR tyrosine kinase inhibitors (TKIs) [1] Group 1 - Kelun Pharmaceutical's subsidiary, Kelun Biotech, received approval from the National Medical Products Administration (NMPA) for sac-TMT for a third indication [1] - Sac-TMT is the first and only ADC globally that has shown significant overall survival (OS) benefits compared to platinum-based doublet chemotherapy [1]

Group 1 - The core viewpoint of the report is that the company, InnoCare Pharma-B (09606), is rated as outperforming the industry, with a reasonable market value of HKD 37.9 billion and a target price of HKD 430, indicating a potential upside of 20.1% from the current stock price [1] - The ADC (Antibody-Drug Conjugate) market is one of the most promising and fastest-growing drug forms globally, with an estimated market size of approximately USD 10.4 billion in 2023, projected to reach USD 115.1 billion by 2032 [2] - InnoCare Pharma has established four unique ADC technology platforms and has secured licensing agreements with multinational pharmaceutical companies, with a total transaction value exceeding USD 6 billion [3] Group 2 - The first ADC is expected to submit a listing application in 2025, with notable pipelines including DB-1303 for endometrial cancer and breast cancer, DB-1311 showing potential in prostate cancer, and advancements in dual-antibody ADCs [4] - The report highlights a key difference from market sentiment, emphasizing the investment value of the company as a validated platform innovator in the ADC field, which may incubate more valuable pipelines in the long term [5]

中国生物制药(01177)发布公告，公司全资附属公司礼新医药科技(上海)有限公司("礼新医药")自主研发 的国家1类创新药LM-350"CDH17抗体偶联药物(ADC)"在澳洲开展的I期临床试验已顺利完成首例患者入 组，标志着这一创新疗法正式进入临床开发阶段。 LM-350是基于礼新医药新一代ADC技术平台LM-ADCTM开发的一款靶向CDH17的ADC，能够高度选 择性地结合CDH17，具有很强的内化能力。LM-350采用IgG1野生型构型，同时具备抗体依赖细胞介导 的细胞毒性作用(ADCC)活性。临床前研究显示，LM-350在多个异种移植模型中表现出显著的抗肿瘤活 性，尤其在对MMAE耐药或伊立替康耐药的结直肠癌细胞中效果突出。 CDH17在多种肿瘤侵袭转移中发挥重要作用，并在约99%的结肠癌、86%的胃腺癌、79%的食管腺癌、 50%的胰腺导管腺癌中高表达。消化道肿瘤(包括结直肠癌、胃癌、胰腺癌、食管癌等)是全球发病率和 死亡率最高的癌症种类之一，2022年全球新发患者数量超过400万人，存在巨大的尚未被满足的临床需 求。 本次临床研究为一项LM-350在晚期实体肿瘤患者中的安全性、耐受性、药代动力学特 ...

Core Viewpoint - China Biopharmaceutical's subsidiary, Lixin Pharmaceutical Technology, has successfully completed the first patient enrollment in the Phase I clinical trial of its innovative drug LM-350, marking the entry of this therapy into clinical development [1][2] Group 1: Product Development - LM-350 is a Class 1 innovative drug developed based on Lixin's next-generation ADC technology platform, targeting CDH17 with high selectivity and strong internalization capability [1] - The drug utilizes an IgG1 wild-type configuration and exhibits antibody-dependent cellular cytotoxicity (ADCC) activity [1] - Preclinical studies have shown significant anti-tumor activity of LM-350 in various xenograft models, particularly in colorectal cancer cells resistant to MMAE or irinotecan [1] Group 2: Clinical Need and Market Potential - CDH17 is highly expressed in approximately 99% of colorectal cancers, 86% of gastric adenocarcinomas, 79% of esophageal adenocarcinomas, and 50% of pancreatic ductal adenocarcinomas, indicating its critical role in tumor invasion and metastasis [1] - Gastrointestinal tumors, including colorectal, gastric, pancreatic, and esophageal cancers, represent one of the highest incidence and mortality rates globally, with over 4 million new patients reported in 2022, highlighting a significant unmet clinical need [1]

Core Viewpoint - The stock of Valiant Biopharma-B (09887) rose over 5% following the announcement of successful patient enrollment in a clinical study for its drug LBL-024, a dual-specific antibody targeting PD-L1 and 4-1BB, which is aimed at treating advanced melanoma and potentially lung neuroendocrine cancer [1] Company Developments - Valiant Biopharma announced the successful enrollment of the first patient in an Ib/II clinical study (NCT07099430) for LBL-024, which will explore its efficacy as a monotherapy or in combination for first-line treatment of advanced melanoma [1] - LBL-024 is noted as the first targeted therapy for the 4-1BB receptor to reach the registration clinical stage globally, with the potential to become the first approved drug for advanced lung neuroendocrine cancer [1] Industry Insights - CMB International released a report highlighting Valiant Biopharma's focus on developing immunotherapies involving immune checkpoint inhibitors and co-stimulatory agonists, while also expanding into other areas such as CD3T cell connectors and antibody-drug conjugates (ADC) [1] - The company has developed proprietary platforms, LeadsBody and X-body, which serve as engines for continuous drug discovery [1] - The report expresses optimism regarding Valiant Biopharma's development of PD-L1/4-1BB and TCE as next-generation immuno-oncology therapies [1]

Group 1 - The Hang Seng Index Company announced the inclusion of InnoCare Pharma-B (09606) into the Hang Seng Composite Index, effective after market close on September 5, 2025, with trading starting on September 8, 2025 [1] - InnoCare Pharma-B is likely to be included in the Hong Kong Stock Connect due to meeting various criteria such as market capitalization, liquidity, and listing duration [1] - The company's key product, DB-1310, has received Fast Track designation from the FDA for treating adult patients with advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed on prior EGFR TKI therapy and platinum-based chemotherapy [1] Group 2 - DB-1310 is a next-generation ADC product targeting HER3, developed using the company's proprietary DITAC technology platform [2] - Initial results from the Phase I/IIa clinical trial (NCT05785741) of DB-1310 were presented at the 2025 American Society of Clinical Oncology (ASCO) annual meeting, showing encouraging efficacy and manageable safety in patients with advanced solid tumors who failed standard treatments [2]

Core Viewpoint - Fuhong Hanlin (02696) has seen a significant stock price increase following the announcement of a strategic partnership with Qide Pharmaceutical for the development and commercialization of the innovative HER2-targeted antibody-drug conjugate (ADC) GQ1005 in China and select overseas markets [1] Group 1: Strategic Partnership - Fuhong Hanlin has entered into a strategic collaboration with Qide Pharmaceutical to obtain exclusive rights for the development and commercialization of GQ1005, which is currently in Phase III clinical trials for HER2-positive breast cancer [1] - GQ1005 is developed using Qide Pharmaceutical's proprietary enzyme-mediated site-specific conjugation technology, showing comparable anti-tumor activity to Trastuzumab in preclinical studies [1] Group 2: Market Position and Product Pipeline - Breast cancer is a core therapeutic area for Fuhong Hanlin, which has established a diversified product pipeline covering the entire disease course and molecular subtypes of breast cancer [1] - The company has built a global commercialization network through its own commercial team and partnerships with overseas collaborators, aiming to continuously unlock the commercial value of its breast cancer pipeline [1]

Core Insights - China National Pharmaceutical Group's subsidiary, Lixin Pharmaceutical Technology, has developed an innovative drug LM-302, which has been included in the Breakthrough Therapy Designation (BTD) program by the National Medical Products Administration (NMPA) for treating CLDN18.2 positive locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma in combination with PD-1 monoclonal antibody [1][2] - LM-302 is a potential first-in-class antibody-drug conjugate (ADC) targeting CLDN18.2, showing clinical efficacy in patients with gastric cancer, pancreatic cancer, and biliary tract cancer, with benefits observed even in patients with low expression of Claudin18.2 and PD-L1 [1] - Recent data presented at the 2025 American Society of Clinical Oncology (ASCO) annual meeting indicated an overall response rate (ORR) of 65.9% and a disease control rate (DCR) of 85.4% in 41 evaluable patients, with ORR of 71.9% and DCR of 96.9% in 32 patients with CLDN18.2 expression ≥25% [1] Clinical Development - LM-302 is currently undergoing Phase III clinical trials in China for treating CLDN18.2 positive locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma after progression on two or more lines of systemic therapy [2] - The inclusion in the Breakthrough Therapy Designation program is expected to expedite the approval process for LM-302, providing innovative treatment options for more CLDN18.2 positive gastric cancer patients [2]